leadf
logo-loader
viewInternational Stem Cell Corp.
(
OTCQX:ISCO
)

International Stem Cell Corp. to present at American Society of Gene and Cell Therapy

stem_cell_research_350_4dd2ce2d25e64.jpg

International Stem Cell Corp. (ISC) (OTCBB:ISCO) announced Tuesday its plans to present at the American Society of Gene and Cell Therapy's Annual Meeting in Seattle, Washington, this month.

Two of the company's scientists will present the results of the company's experiements on the therapeutic use of human parthenogenetic stem cells (hpSC), which have the capacity to essentially become almost any cell type in the body.

International Stem Cell's scientists have developed the first hpSC line that can be a source of therapeutic cells, with minimal immune rejection. The company's parthenogenetic process to create stem cells avoids ethical issues by using unfertilized human eggs.

At the upcoming meeting, vice president Dr. Ruslan Semechkin will give a presentation called "Neutral Stem Cells of Parthenogenetic Origin" on May 19.

Meanwhile, on May 21, director of research and therapeutic development, Dr. Nikolay Turovets, is slated to introduce a poster presentation entitled "An in vitro Analog of the Primitive Streak to Derive High-Purity Definitive Endoderm Lineages Uncontaminated with Undifferentiated Cells".

The American Society of Gene & Cell Therapy (ASGCT) is a not-for-profit medical and scientific organization that is dedicated to developing and applying genetic and cellular therapies. The ASGCT presents new findings in gene and cell therapies at its annual meeting, attended by over 2,000 scientists and post-doctoral fellows worldwide.

Quick facts: International Stem Cell Corp.

Follow
OTCQX:ISCO

Price: 0.56 USD

Market Cap: $4.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Iofina says 'our business has been strong' reporting record revenue and...

Iofina PLC (AIM:IOF, OTC:IOFNF, FRA:IF7) (AIM:IOF, OTC:IOFNF, FRA:IF7) Tom Becker joins Proactive London to explain what drove their record revenue and profit in the first half.  Debt also fell in the first half of the year despite production outages caused by extreme weather and reduced...

2 days, 11 hours ago

2 min read